0001603756-24-000017.txt : 20240108 0001603756-24-000017.hdr.sgml : 20240108 20240108084731 ACCESSION NUMBER: 0001603756-24-000017 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Axonics, Inc. CENTRAL INDEX KEY: 0001603756 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 454744083 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38721 FILM NUMBER: 24518564 BUSINESS ADDRESS: STREET 1: 26 TECHNOLOGY DRIVE CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-396-6322 MAIL ADDRESS: STREET 1: 26 TECHNOLOGY DRIVE CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: Axonics Modulation Technologies, Inc. DATE OF NAME CHANGE: 20140326 8-K 1 axnx-20240108.htm 8-K axnx-20240108
false000160375600016037562024-01-082024-01-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
  _________________________________________________________________
FORM 8-K
 _________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 8, 2024
_________________________________________________________________
Axonics, Inc.
(Exact name of registrant as specified in its charter)
_________________________________________________________________
Delaware 001-38721 45-4744083
(State or other jurisdiction
of incorporation)		 (Commission File Number) (I.R.S. Employer
Identification No.)
26 Technology Drive
Irvine, California 92618
(Address of principal executive offices) (Zip Code)
(949) 396-6322
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
  _________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ☒Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of classTrading symbolName of exchange on which registered
Common stock, par value $0.0001 per shareAXNXNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


Item 2.02.    Results of Operations and Financial Condition.

On January 8, 2024, Axonics, Inc., a Delaware corporation (the “Company” or “Axonics”), issued a press release announcing its preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023, based on the information and data currently available.

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference; provided, however, that information on or connected to the Company’s website or the website of any third-party hyperlinked from or referenced in the press release is expressly not incorporated by reference into or intended to be filed as a part of this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01.    Regulation FD.

On January 8, 2024, the Company issued a press release announcing that the Company and Boston Scientific Corporation, a Delaware corporation (“Boston Scientific”), have executed a definitive agreement pursuant to which the Company will be acquired by Boston Scientific on the terms and subject to the conditions set forth in the definitive agreement. The acquisition is expected to close in the first half of 2024, subject to customary closing conditions.

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference; provided, however, that information on or connected to the Company’s website or the website of any third-party hyperlinked from or referenced in the press release is expressly not incorporated by reference into or intended to be filed as a part of this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, as well as Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Additional Information and Where to Find It

In connection with the contemplated transaction, Axonics intends to file with the U.S. Securities and Exchange Commission (“SEC”) preliminary and definitive proxy statements relating to the contemplated transaction and other relevant documents. The definitive proxy statement will be mailed to Axonics’ stockholders as of a record date to be established for voting on the contemplated transaction and any other matters to be voted on at the special meeting. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, ANY OTHER SOLICITING MATERIALS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE CONTEMPLATED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AXONICS, BOSTON SCIENTIFIC AND THE CONTEMPLATED TRANSACTION. Investors and security holders may obtain free copies of these documents (when they are available) on the SEC’s website at www.sec.gov, on Axonics’ website at www.axonics.com or by contacting Axonics’ Investor Relations department via email at IR@axonics.com.

Participants in the Solicitation

Axonics and its directors and executive officers may, under SEC rules, be deemed participants in the solicitation of proxies from the stockholders of Axonics in connection with the contemplated transaction and any other matters to be voted on at the special meeting. Information regarding the names, affiliations and interests of such directors and executive officers will be included in the preliminary and definitive proxy statements (when available) for the contemplated transaction. Additional information regarding such directors and executive officers is included in Axonics’ Definitive Proxy Statement on Schedule 14A for Axonics’ 2023 Annual Meeting of Stockholders, which was filed with the SEC on May 1, 2023 (and specifically, the following sections: “Security Ownership of Certain Beneficial Owners, Executive Officers and Directors”, “Certain Relationships and Related-Party Transactions”, “Executive Officers”, “Proposal 1–Election of Directors”, “Director Compensation”, and “Executive Compensation”) and in Axonics’ Current Report on Form 8-K, which was filed with the SEC on October 4, 2023. To the extent holdings of the Company’s securities by the directors or executive officers have changed since the amounts set forth in the Definitive Proxy Statement on Schedule 14A for Axonics’ 2023 Annual Meeting of Stockholders, such changes have been or will be reflected on Initial Statement of Beneficial Ownership of


Securities on Form 3, Statement of Changes in Beneficial Ownership on Form 4, or Annual Statement of Changes in Beneficial Ownership on Form 5 filed with the SEC, which are available at EDGAR Search Results (https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001603756&type=&dateb=&owner=only&count=40&search_text=). These documents (when available) are available free of charge as described in the preceding section.

Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of Axonics’ stockholders in connection with the contemplated transaction and any other matters to be voted upon at the special meeting will be set forth in the preliminary and definitive proxy statements (when available) for the contemplated transaction. These documents (when available) are available free of charge as described in the preceding section.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words like “may,” “will,” “likely,” “should,” “expect,” “anticipate,” “future,” “plan,” “believe,” “intend,” “goal,” “seek,” “estimate,” “project,” “continue,” and variations of such words and similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, assumptions, and uncertainties, including, but not limited to, risks related to: the ability of the parties to consummate the contemplated transaction in a timely manner or at all; the satisfaction or waiver of the conditions to closing the contemplated transaction, including the failure to obtain antitrust or other regulatory approvals and clearances or approval of Axonics’ stockholders; potential delays in consummating the contemplated transaction; the occurrence of any event, change or other circumstance or condition that could give rise to termination of the merger agreement for the contemplated transaction; the ability to realize the anticipated benefits of the contemplated transaction; the ability to successfully integrate the businesses; the effect of the announcement or pendency of the contemplated transaction on Axonics’ business relationships, operating results and business generally; significant transaction costs and unknown liabilities; and litigation or regulatory actions related to the contemplated transaction. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

The forward-looking statements included in this Current Report on Form 8-K are made only as of the date of this Current Report on Form 8-K, and except as otherwise required by federal securities law, Axonics does not assume any obligation nor does it intend to publicly update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. Further information on factors that could cause actual results to differ materially from the results anticipated by Axonics’ forward-looking statements is included in the reports Axonics has filed or will file with the SEC, including Axonics’ Annual Report on Form 10-K for the year ended December 31, 2022 and Axonics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. These filings, when available, are available on the investor relations section of Axonics’ website at www.axonics.com and on the SEC’s website at www.sec.gov.

Item 9.01.    Financial Statements and Exhibits.
    (d) Exhibits.
Exhibit No.Description
99.1
99.2
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 AXONICS, INC.
Date: January 8, 2024 By: /s/ Raymond W. Cohen
  Raymond W. Cohen
  Chief Executive Officer

 EX-99.1 2 axnx-010824xex991.htm EX-99.1 Document

Exhibit 99.1
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue

IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023.
“The continued strong performance of Axonics reflects the physician community’s preference and enthusiasm for our best-in-class incontinence products,” said Raymond W. Cohen, chief executive officer. “Revenue grew 27% in 4Q23 and 34% in FY23, driven by higher utilization and share of wallet at existing customers and the onboarding of new accounts. In 2023, our team is humbled and gratified that clinicians used Axonics therapies to treat approximately 100,000 incontinence patients globally.”
The preliminary revenue results below are unaudited and remain subject to adjustment. Axonics will provide complete financial results in its Form 10-K filing in February.

4Q23 Revenue
•Total company net revenue is expected to be $109.3 to $109.7 million, an increase of 27% compared to the prior year period.
◦Sacral neuromodulation revenue is expected to be $88.3 to $88.5 million, an increase of 26% compared to the prior year period.
◦Bulkamid revenue is expected to be $21.0 to $21.2 million, an increase of 35% compared to the prior year period.

Fiscal Year 2023 Revenue
•Total company net revenue is expected to be approximately $366.1 million, an increase of 34% compared to fiscal year 2022.
◦Sacral neuromodulation revenue is expected to be approximately $291.7 million, an increase of 31% compared to fiscal year 2022.
◦Bulkamid revenue is expected to be approximately $74.4 million, an increase of 44% compared to fiscal year 2022.

J.P. Morgan Healthcare Conference
Due to the pending transaction with Boston Scientific Corporation (NYSE: BSX) that was announced this morning, Axonics will no longer be participating in the J.P. Morgan healthcare conference.

About Axonics
Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023 Financial Times ranking of the fastest growing companies in the Americas after being ranked No. 1 in 2022.
Axonics® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s


best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. For more information, visit www.axonics.com.

Additional Information and Where to Find It
In connection with the contemplated transaction, Axonics intends to file with the U.S. Securities and Exchange Commission (“SEC”) preliminary and definitive proxy statements relating to the contemplated transaction and other relevant documents. The definitive proxy statement will be mailed to Axonics’ stockholders as of a record date to be established for voting on the contemplated transaction and any other matters to be voted on at the special meeting. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, ANY OTHER SOLICITING MATERIALS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE CONTEMPLATED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AXONICS, BOSTON SCIENTIFIC AND THE CONTEMPLATED TRANSACTION. Investors and security holders may obtain free copies of these documents (when they are available) on the SEC’s website at www.sec.gov, on Axonics’ website at www.axonics.com or by contacting Axonics’ Investor Relations department via email at IR@axonics.com.

Participants in the Solicitation
Axonics and its directors and executive officers may, under SEC rules, be deemed participants in the solicitation of proxies from the stockholders of Axonics in connection with the contemplated transaction and any other matters to be voted on at the special meeting. Information regarding the names, affiliations and interests of such directors and executive officers will be included in the preliminary and definitive proxy statements (when available) for the contemplated transaction. Additional information regarding such directors and executive officers is included in Axonics’ Definitive Proxy Statement on Schedule 14A for Axonics’ 2023 Annual Meeting of Stockholders, which was filed with the SEC on May 1, 2023 (and specifically, the following sections: “Security Ownership of Certain Beneficial Owners, Executive Officers and Directors”, “Certain Relationships and Related-Party Transactions”, “Executive Officers”, “Proposal 1–Election of Directors”, “Director Compensation”, and “Executive Compensation”) and in Axonics’ Current Report on Form 8-K, which was filed with the SEC on October 4, 2023. To the extent holdings of the Company’s securities by the directors or executive officers have changed since the amounts set forth in the Definitive Proxy Statement on Schedule 14A for Axonics’ 2023 Annual Meeting of Stockholders, such changes have been or will be reflected on Initial Statement of Beneficial Ownership of Securities on Form 3, Statement of Changes in Beneficial Ownership on Form 4, or Annual Statement of Changes in Beneficial Ownership on Form 5 filed with the SEC, which are available at EDGAR Search Results (sec.gov). These documents (when available) are available free of charge as described in the preceding section.
Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of Axonics’ stockholders in connection with the contemplated transaction and any other matters to be voted upon at the special meeting will be set forth in the preliminary and definitive proxy statements (when available) for the contemplated transaction. These documents (when available) are available free of charge as described in the preceding section.



Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words like “may,” “will,” “likely,” “should,” “expect,” “anticipate,” “future,” “plan,” “believe,” “intend,” “goal,” “seek,” “estimate,” “project,” “continue,” and variations of such words and similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, assumptions, and uncertainties, including, but not limited to, risks related to: the ability of the parties to consummate the contemplated transaction in a timely manner or at all; the satisfaction or waiver of the conditions to closing the contemplated transaction, including the failure to obtain antitrust or other regulatory approvals and clearances or approval of Axonics’ stockholders; potential delays in consummating the contemplated transaction; the occurrence of any event, change or other circumstance or condition that could give rise to termination of the merger agreement for the contemplated transaction; the ability to realize the anticipated benefits of the contemplated transaction; the ability to successfully integrate the businesses; the effect of the announcement or pendency of the contemplated transaction on Axonics’ business relationships, operating results and business generally; significant transaction costs and unknown liabilities; and litigation or regulatory actions related to the contemplated transaction. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
The forward-looking statements included in this press release are made only as of the date of this press release, and except as otherwise required by federal securities law, Axonics does not assume any obligation nor does it intend to publicly update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. Further information on factors that could cause actual results to differ materially from the results anticipated by Axonics’ forward-looking statements is included in the reports Axonics has filed or will file with the SEC, including Axonics’ Annual Report on Form 10-K for the year ended December 31, 2022 and Axonics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. These filings, when available, are available on the investor relations section of Axonics’ website at www.axonics.com and on the SEC’s website at www.sec.gov.

Axonics contact:
Neil Bhalodkar
949-336-5293
IR@axonics.com

 EX-99.2 3 axnx-010824xex992.htm EX-99.2 Document

Exhibit 99.2
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific

IRVINE, Calif – (BUSINESS WIRE) – Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion.
Axonics brings a complementary product portfolio to the Boston Scientific Urology business. Axonics has pioneered and introduced significant enhancements to sacral neuromodulation therapy for bladder and bowel dysfunction and urethral bulking for women with stress urinary incontinence, both of which are among the fastest growing segments in urology.
“Since its founding ten years ago, Axonics has focused on developing best-in-class solutions for people with incontinence, providing clinicians and their patients with strong clinical support, and raising public awareness of our advanced therapies,” said Raymond W. Cohen, chief executive officer. “The success of Axonics is a testament to our mission-driven employees and their commitment to innovation, quality and teamwork. Our team is looking forward to the global impact we can make as part of Boston Scientific as we endeavor to bring these life-changing therapies to more patients than ever before.”
The boards of directors of Axonics and Boston Scientific have unanimously approved the transaction, which is expected to close in the first half of 2024 after satisfaction of customary closing conditions, including approval of Axonics’ stockholders and receipt of required regulatory approvals. Upon completion of the transaction, Axonics will become a wholly owned subsidiary of Boston Scientific.
J.P. Morgan Securities LLC is serving as financial advisor and K&L Gates LLP is serving as legal counsel to Axonics.

About Axonics
Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023 Financial Times ranking of the fastest growing companies in the Americas after being ranked No. 1 in 2022.
Axonics® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. For more information, visit www.axonics.com.

Additional Information and Where to Find It
In connection with the contemplated transaction, Axonics intends to file with the U.S. Securities and Exchange Commission (“SEC”) preliminary and definitive proxy statements relating to the contemplated transaction and other relevant documents. The definitive proxy statement will be mailed to Axonics’ stockholders as of a record date to be established for voting on the contemplated transaction and any other matters to be voted on at the special meeting. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, ANY OTHER SOLICITING MATERIALS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION


WITH THE CONTEMPLATED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AXONICS, BOSTON SCIENTIFIC AND THE CONTEMPLATED TRANSACTION. Investors and security holders may obtain free copies of these documents (when they are available) on the SEC’s website at www.sec.gov, on Axonics’ website at www.axonics.com or by contacting Axonics’ Investor Relations department via email at IR@axonics.com.

Participants in the Solicitation
Axonics and its directors and executive officers may, under SEC rules, be deemed participants in the solicitation of proxies from the stockholders of Axonics in connection with the contemplated transaction and any other matters to be voted on at the special meeting. Information regarding the names, affiliations and interests of such directors and executive officers will be included in the preliminary and definitive proxy statements (when available) for the contemplated transaction. Additional information regarding such directors and executive officers is included in Axonics’ Definitive Proxy Statement on Schedule 14A for Axonics’ 2023 Annual Meeting of Stockholders, which was filed with the SEC on May 1, 2023 (and specifically, the following sections: “Security Ownership of Certain Beneficial Owners, Executive Officers and Directors”, “Certain Relationships and Related-Party Transactions”, “Executive Officers”, “Proposal 1–Election of Directors”, “Director Compensation”, and “Executive Compensation”) and in Axonics’ Current Report on Form 8-K, which was filed with the SEC on October 4, 2023. To the extent holdings of the Company’s securities by the directors or executive officers have changed since the amounts set forth in the Definitive Proxy Statement on Schedule 14A for Axonics’ 2023 Annual Meeting of Stockholders, such changes have been or will be reflected on Initial Statement of Beneficial Ownership of Securities on Form 3, Statement of Changes in Beneficial Ownership on Form 4, or Annual Statement of Changes in Beneficial Ownership on Form 5 filed with the SEC, which are available at EDGAR Search Results (sec.gov). These documents (when available) are available free of charge as described in the preceding section.
Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of Axonics’ stockholders in connection with the contemplated transaction and any other matters to be voted upon at the special meeting will be set forth in the preliminary and definitive proxy statements (when available) for the contemplated transaction. These documents (when available) are available free of charge as described in the preceding section.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words like “may,” “will,” “likely,” “should,” “expect,” “anticipate,” “future,” “plan,” “believe,” “intend,” “goal,” “seek,” “estimate,” “project,” “continue,” and variations of such words and similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, assumptions, and uncertainties, including, but not limited to, risks related to: the ability of the parties to consummate the contemplated transaction in a timely manner or at all; the satisfaction or waiver of the conditions to closing the contemplated transaction, including the failure to obtain antitrust or other regulatory approvals and clearances or approval of Axonics’ stockholders; potential delays in consummating the contemplated transaction; the occurrence of any event, change or other circumstance or condition that could give rise to termination of the merger agreement for the contemplated transaction; the ability to realize the anticipated benefits of the contemplated transaction; the ability to successfully integrate the businesses; the effect of the announcement or pendency of the contemplated transaction on Axonics’ business relationships, operating results and business generally; significant transaction costs and


unknown liabilities; and litigation or regulatory actions related to the contemplated transaction. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
The forward-looking statements included in this press release are made only as of the date of this press release, and except as otherwise required by federal securities law, Axonics does not assume any obligation nor does it intend to publicly update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. Further information on factors that could cause actual results to differ materially from the results anticipated by Axonics’ forward-looking statements is included in the reports Axonics has filed or will file with the SEC, including Axonics’ Annual Report on Form 10-K for the year ended December 31, 2022 and Axonics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. These filings, when available, are available on the investor relations section of Axonics’ website at www.axonics.com and on the SEC’s website at www.sec.gov.

Axonics contact:
Neil Bhalodkar
949-336-5293
IR@axonics.com

 EX-101.SCH 4 axnx-20240108.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 axnx-20240108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 axnx-20240108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover Page
Jan. 08, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001603756
Document Type 8-K
Document Period End Date Jan. 08, 2024
Entity Registrant Name Axonics, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38721
Entity Tax Identification Number 45-4744083
Entity Address, Address Line One 26 Technology Drive
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92618
City Area Code 949
Local Phone Number 396-6322
Written Communications false
Soliciting Material true
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol AXNX
Security Exchange Name NASDAQ
XML 8 axnx-20240108_htm.xml IDEA: XBRL DOCUMENT 0001603756 2024-01-08 2024-01-08 false 0001603756 8-K 2024-01-08 Axonics, Inc. DE 001-38721 45-4744083 26 Technology Drive Irvine CA 92618 949 396-6322 false true false false Common stock, par value $0.0001 per share AXNX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .]%*%@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #O12A8WRM"V^\ K @ $0 &1O8U!R;W!S+V-O&ULS9+; M2@,Q$(9?17*_.WLH'L(V-XI7"H(%Q;N03-O0S8%D9+=O[VYLMX@^@)>9^?/- M-S"="ESYB"_1!XQD,%V-MG>)J[!F>Z+ 9+:HY6IG!)N:FY]M)*F9]Q!D.H@ M=PA-55V#19):DH096(2%R$2G%5<1)?EXPFNUX,-G[#-,*\ >+3I*4)Q[^ "F&&$T:;O NJ%F*M_8G,'V"DY)K.DAF$HAS;GIAUJ>']^>LWK%L8E MDD[A]"L93L> :W:>_-;>/VP>F6BJ9E54=5'=;NJ6KVYX<_&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #O12A8]K*P6TL$ !Y$ & 'AL+W=OGG7X0ML":V)(KR0'^ M?8\,L=E=<\R'!,OXO'YT=/1*8KB1ZD4GC!FRS5*A1TYB3'[CNCI*6$;UER,"D7;*:(+K*,JMTM M2^5FY/C.VXUGODZ,O>&.ASE=LSDS?^8S!2VW4HEYQH3F4A#%5B-GXM_.9XE8BF+C)6@\/'*IBQ-K1)P_'<0=:IWVL#C MZS?UA[+ST)DEU6PJT\\\-LG(Z3LD9BM:I.99;GYCAPY=6[U(IKK\3S;[9\/0 M(5&ACRE>FR P&8.@:T+-WW>@0>[N/#4[$_D[%%?'Z%R3P M@O#K'K5'P=3'T\@6J,X<^0AY2NF^CP^!5--4,XPHHC1'7NA>%F1Z9 MHFA*'D7,MN0]VS41X4J>YT%N.KWK+H)U76%=HV)W,BK*["QV>6,UX>']R_<( M1+>"Z)X',6.*RYCQ5;[YQQ>V9K;BL<()]HUDB& MZTRV4O!(7\#(1U<(5[_BZI_#!6I2Y5)1:Y<79&X@;40J,I4%%!K4FXP;87'Q MNWN$<% 1#LXA?. I(T]%MF2J"037@%*_[/1[@8_P^%YMF]XY1 NZ)8\QU!M? M\:A,',+7(AE>7X:],/3Z'8SPR-C]1&-&+BD$0ZL7 ?^L5:!"FTEM8#7XF^1DEDB!&4>+2&?0O>QV@@ CJM< M'S?OSXH;PP0D)LL*<3 -W4B%"[7M)OS:_GWG+QA);?@!;L]O*2/WVRBA8LU.;A]; MA)XF\[O)'TU,[M%!TA[*/U);1YJD; 5*WE4/7%OMS[G[AI%Y>;9<2@,GU?(R M810F@WT OE]):=X:]KA:_=HP_A]02P,$% @ [T4H6)^@&_"Q @ X@P M T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%? ME5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK= MT*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G M7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y M*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W M7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M, MDP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1! MBEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_ MD/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[ M:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y M_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J6 M9? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE M 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ [T4H M6)>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5 MN %(MB6/:(7->=I3W; M+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II% MR=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/4 M6PQFN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO40 M9.B1P74&0ZRQB28)UD-N5G0&3K;V"%TH?653#@%%G=W4Q7/4 6_*P>-HK(0* M Y1OJA65UY**+2?=T>M,[Q\FCUI&Z]Q*N??P2K8<&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_ M[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ M0=@S9)[NF:*'3^ 5!+ P04 M " #O12A899!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RM MDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C> MO,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0 MP1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH% M.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D M(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S6 M3AI_YHOA/UY_ 5!+ 0(4 Q0 ( .]%*%@'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ [T4H6-\K M0MOO *P( !$ ( !KP &1O8U!R;W!S+V-O&UL M4$L! A0#% @ [T4H6)E&PO=V]R:W-H965T&UL M4$L! A0#% @ [T4H6)^@&_"Q @ X@P T ( !CPP M 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! M A0#% @ [T4H6"0>FZ*M ^ $ !H ( !N!$ 'AL M+U]R96QS+W=O9(9 M 0 SP, !, ( !G1( %M#;VYT96YT7U1Y<&5S72YX;6Q0 52P4& D "0 ^ @ YQ, end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://axonicsmodulation.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports axnx-20240108.htm axnx-20240108.xsd axnx-20240108_lab.xml axnx-20240108_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "axnx-20240108.htm": { "nsprefix": "axnx", "nsuri": "http://axonicsmodulation.com/20240108", "dts": { "inline": { "local": [ "axnx-20240108.htm" ] }, "schema": { "local": [ "axnx-20240108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "axnx-20240108_lab.xml" ] }, "presentationLink": { "local": [ "axnx-20240108_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://axonicsmodulation.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "axnx-20240108.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "axnx-20240108.htm", "first": true, "unique": true } } }, "tag": { "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001603756-24-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001603756-24-000017-xbrl.zip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end